33-104 : Drug Use-Results Survey of OPDIVO

JRCT ID: jRCT2011230029

Registered date:04/08/2023

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chem
• Date of first enrollment: 18/12/2018
• Target sample size: 100
• Study type: Observational

Outcome(s)

Primary Outcome

[Safety]
a) Occurrence status of adverse drug reactions and infections,
b) Factors that are considered to affect safety
c) Adverse events

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Patients with unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy, who have recieved OPDIVO for the first time
• Exclude criteria: Patients who have received OPDIVO previously

Related Information

• Primary Sponsor: Kuro Toshihiko